PROPHETIC
PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Sponsor study identifier
observational
10,000
5 countries
41
Study Start
October 1, 2019
Actual (reported)Primary Completion
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 11, 2019
Actual (reported)August 14, 2019
Actual (reported)October 1, 2019
Actual (reported)October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Measured biological features at baseline (pre-treatment) and after 1st dose administration (on-treatment) and during treatment (optional)
Biological features are analyzed in biological samples taken from the patients as part of the study
Measured biological features are analyzed in samples taken at baseline (prior treatment) and after the 1st dose administration (on-treatment) and during treatment (optional)
Overall response as determined by RECIST 1.1 or any other validated clinical scales for response, every 3 months or according to the standard of care
Overall response as determined by RECIST 1.1 or any other validated clinical scales for response, every 3 months or according to the standard of care
Every 3 months or according to the standard of care
Progression Free Survival (PFS)
Stage IV NSCLC patients treated with ICI or a combination of ICI and chemotherapy in any line of treatment, or with chemotherapy as a first line treatment.
Patients with Stage III unresectable NSCLC treated with ICI therapy or ICI in combination with chemotherapy
Stage IV malignant melanoma patients treated with any regimen that includes ICI therapy as a monotherapy or in combination with targeted therapy in any line of treatment. In specific sites, Stage IV melanoma patients treated with targeted therapy (as a reference population).
Stage IIIb-d malignant melanoma patients treated with any regimen that includes ICI therapy as monotherapy or in combination with targeted therapy as adjuvant therapy.
Collect at least two plasma samples
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
1. Stage IV NSCLC patients treated with ICI or a combination of ICI and chemotherapy in any line of treatment, or with chemotherapy as a first line treatment. 2. Stage III unresectable NSCLC patients treated with ICI therapy or ICI in combination with chemotherapy. 3. Stage IV malignant melanoma patients treated with any regimen that includes ICI therapy as a monotherapy or in combination with targeted therapy in any line of treatment. In specific sites, Stage IV melanoma patients treated with targeted therapy (as a reference population). 4. Stage IIIb-d malignant melanoma patients treated with any regimen that includes ICI therapy as monotherapy or in combination with targeted therapy as adjuvant therapy. 5. Stage IV SCLC patients treated with any regimen of ICI, chemotherapy or combination of ICI and chemotherapy in any line of treatment.
Birmingham VAHCS
Birmingham, Alabama, 35233, United States
Mayo Clinic
Jacksonville, Florida, 32224, United States
University of Miami
Miami, Florida, 33136, United States
Florida Cancer Specialist and Research Institute
Orlando, Florida, 32827, United States
Protean Biodiagnosics
Orlando, Florida, 32827, United States
Northwest Community Healthcare
Rolling Meadows, Illinois, 60008, United States
Helen Nassif Community Cancer Center
Cedar Rapids, Iowa, 52403, United States
Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol. 2016 Oct;13(10):611-26. doi: 10.1038/nrclinonc.2016.57. Epub 2016 Apr 26.
Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 2007 Aug 1;67(15):7055-8. doi: 10.1158/0008-5472.CAN-07-0905.
plasma samples.
Alona Zer, MD
Rambam Health Care Campus
Michal Lotem, MD
Hadassah Medical Organization
Jair Bar, MD
Sheba Medical Center
Maya Gottfried, MD
Meir Medical Center
First Submitted
August 11, 2019
First Posted
August 14, 2019
Study Start
October 1, 2019
Actual (reported)Primary Completion
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Collect Progression Free Survival (PFS) dates
At progression during treatment
Overall survival or last follow-up
Collect overall survival or last follow-up dates
Overall survival or last follow-up
Adverse Events (AE)
Adverse events (AE) during treatment and until the end of study
Stage IV SCLC patients treated with any regimen of ICI, chemotherapy or combination of ICI and chemotherapy in any line of treatment.
Contact the study team to confirm eligibility.
Rutgers Cancer Institute
New Brunswick, New Jersey, 08903, United States
Roswell Park
Buffalo, New York, 14263, United States
West Clinic
Germantown, Tennessee, 38138, United States
Michael E. Debakey VA Medical Center
Houston, Texas, 77030, United States
151-Christus Health St. Michael
Texarkana, Texas, 75503, United States
Asklepois
Gauting, 82131, Germany
Thoraxklinik Heidelberg gGmbH
Heidelberg, 69126, Germany
Haemek Medical Center
Afula, Israel
Barzilai Medical Center
Ashkelon, Israel
Soroka Medical Center
Beersheba, Israel
Shamir Medical Center
Be’er Ya‘aqov, Israel
Bnai Zion Medical Center
Haifa, Israel
Rambam Medical Center
Haifa, Israel
Hadassah Medcial Center
Jerusalem, Israel
Meir medical center
Kfar Saba, Israel
Rabin Medical Center
Petah Tikva, Israel
Kaplan Medical Center
Rehovot, Israel
Assuta Medical Cetner
Tel Aviv, Israel
Sheba Medical Center
Tel Aviv, Israel
Sourasky Medical Center
Tel Aviv, Israel
Sheba medical center
Tel Litwinsky, Israel
044 Hospital Universitario Virgen Macarena
Seville, Spain
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Royal Bournemouth General Hospital
Bournemouth, United Kingdom
Bradford Teaching Hospitals
Bradford, BD9 6RJ, United Kingdom
Cheltenham General Hospital
Cheltenham, United Kingdom
Withybush Hospital
Haverfordwest, SA61 2PZ, United Kingdom
Mount Vernon Cancer Centre
Northwood, United Kingdom
The Shrewsbury and Telford Hospital
Shrewsbury, United Kingdom
South Tyneside
South Shields, NE34 0PL, United Kingdom
Lister Hospital
Stevenage, United Kingdom
Sunderland Royal Hospital
Sunderland, SR4 7TP, United Kingdom
Swansea Bay UHB Singleton Hospital
Swansea, United Kingdom
Torbay Hospital
Torquay, United Kingdom
Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets. 2005 Nov;5(7):551-9. doi: 10.2174/156800905774574020.
Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, Elon Y, Sela I, Yellin B, Lahav C, Raveh S, Reiner-Benaim A, Reinmuth N, Nechushtan H, Farrugia D, Bustinza-Linares E, Lou Y, Leibowitz R, Kamer I, Zer Kuch A, Moskovitz M, Levy-Barda A, Koch I, Lotem M, Katzenelson R, Agbarya A, Price G, Cheley H, Abu-Amna M, Geldart T, Gottfried M, Tepper E, Polychronis A, Wolf I, Dicker AP, Carbone DP, Gandara DR. Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Mar;8:e2300555. doi: 10.1200/PO.23.00555.
Abed Agbaria, MD
Bnai Zion Medical Center
Ido Wolf, MD
Tel-Aviv Sourasky Medical Center
Mahmud Abu-Amana, MD
haemek medical center
Rivka Katsenelson, MD
Kaplan Medical Center
Alexander Yakobson, MD
Soroka University Medical Center
Tatiana Harkovsky, MD
Barzilai Medical Center
Mor Moskovitz, MD
Rabin Medical Center
Elizabeta Dudnik, MD
Assuta Medical Center
Raya Leibowitz, MD
Assaf-Harofeh Medical Center
Adam Berger, MD
Rutgers Cancer Institute
Jose Lutzky, MD
University of Miami
Antony Magliocco, MD
Protean BioDiagnostics
Gillian Price, MD
Aberdeen Royal Infirmary
Helen Cheley
Swansea Bay UHB - Cancer Institute
Louise Medley, MD
Torbay and South Devon NHS foundation
Tom Geldart, MD
Royal Bournemouth General Hospital Dorset
Anirban Chatterjee, MD
The Shrewsbury and Telford Hospital
Sean Brown, MD
Gloucestershire Hospitals NHS Foundation Trust
Andreas Polychronis, MD
Mount Vernon Cancer Centre
Andreas Polychronis, MD
Lister Hospital
Ari VanderWalde, MD
West Clinic
Davika Das, MD
VAHCS Birmingham
Alison Brewster, MD
Withybush Hospital Hawl Dda University Health Board
Adam Hassani
Sunderland Royal Hospital
Adam Hassani, MD
South Tyneside District
Andrew Conn, MD
Bradford Teaching Hospitals
Yanyan Lou, MD
Mayo Clinic
Igor Puzanov, MD
Roswell Park
Ernesto Bustinza, MD
Florida Cancer Specialists and Research Institute
Huang Quillan, MD
Michael E. DeBakey VA Medical Center
Ronnie Shapira Frommer, MD
Sheba Medical Center
Astrid Ammendola, MD
Asklepios Klinik Gauting GmbH
Petros Christopoulos, MD
Thoraxklinik-Heidelberg gGmbH
Marina Messinger, MD
Northwest Community Healthcare
Sunil Patel, MD
CHRISTUS St. Michael Health System
Bharat P Jenigiri, MD
Physicians Clinic of Iowa
David Vecente, MD
Hospital Universitario Virgen Macarena
Eugenie Younger, MD
Gloucestershire Hospitals NHS Foundation Trust
Study Completion
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 19, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: